Table 1.

Patient characteristics

Clinical and pathologic dataValidation set (n = 100)
Median age, y50 (26-76)
Race
    Caucasian68
    African-American12
    Asian7
    Hispanic13
Histologic type
    Invasive ductal85
    Mixed ductal/lobular8
    Invasive lobular7
Prechemotherapy tumor size
    T0 (with positive axillary node)2
    T18
    T262
    T313
    T415
Clinical N stage
    N027
    N147
    N213
    N313
Nuclear grade
    111
    242
    347
ER status*
    Positive60
    Negative40
HER-2 status
    Positive7
    Negative93
Neoadjuvant chemotherapy
    Weekly T × 12 + FAC × 498
    Thrice weekly T × 12 + FAC × 42
PCR15
Residual disease85
  • *Cases where >10% of tumor cells stained positive for ER with immunohistochemistry were considered positive.

  • Cases that showed either more than three immunohistochemistry staining or had a gene copy number of >2.0 were considered HER-2 “positive.”

  • T, paclitaxel; FAC, 5-FU, doxorubicin, and cyclophosphamide.